AFMD - Affimed Roche commences patient recruitment in Phase 1/2a trial of AFM24 + atezolizumab

Affimed (NASDAQ:AFMD) has initiated patient recruitment for Phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE) AFM24 in combination with Roche’s (OTCQX:RHHBY) atezolizumab. AFM24 is being developed for the treatment of patients with solid tumors. The study will consist of two parts. The first part is a dose escalation phase, aiming to determine the maximum tolerated dose/recommended phase 2 dose of AFM24 + atezolizumab. In the second part, the expansion phase (phase 2a), the goal is to collect preliminary evidence of efficacy as well as to confirm the safety of the therapeutic combination. The trial will include patients with solid tumors, including non-small cell lung cancer, gastric- and gastroesophageal junction adenocarcinoma and pancreatic/hepatocellular/biliary tract cancer. Recently, AFMD reported promising interim results from Phase 1-2 study, evaluating cbNK cells pre-complexed with AFM13.

For further details see:

Affimed, Roche commences patient recruitment in Phase 1/2a trial of AFM24 + atezolizumab